# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

Central Nervous System Lymphoma, Primary

Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 31-40 of 46 results.
Nivolumab Maintenance in Newly Diagnosed PCNSL With Persistent CSF Circulating Tumor DNA After Completion of First-Line Chemotherapy
Status: Recruiting
Last Changed: May 29, 2020
First Received: May 26, 2020
Disease(s): Primary Central Nervous System Lymphoma (PCNSL)
Intervention(s): Nivolumab
Locations: Memoral Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States
Memorial Sloan Kettering Commack (Limited Protocol Activities), Commack, New York, United States
Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison, New York, United States
... and 3 other locations.
BUCYE Conditioning Regimen for PCNSL Undergoing Auto-HSCT
Status: Recruiting
Last Changed: Nov 07, 2018
First Received: Nov 07, 2018
Disease(s): Primary Central Nervous System Lymphoma, Autologous Hematopoietic Stem Cell Transplantation, Conditioning
Intervention(s): Busulfan (BU), Cyclophosphamide (CY), Etoposide (VP-16)
Locations: Department of Hematology,Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extranodal Diffuse Large B-cell Lymphomas
Status: Recruiting
Last Changed: Jun 02, 2020
First Received: Aug 21, 2017
Disease(s): Non-Hodgkin Lymphoma, Lymphoma, Diffuse Large B-Cell Lymphoma, Gray Zone Lymphoma, Primary Central Nervious System Lymphoma
Intervention(s): Pembrolizumab
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Rituximab Plus Methotrexate With or Without Lenalidomide in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma
Status: Recruiting
Last Changed: Jul 22, 2020
First Received: Jul 22, 2020
Disease(s): PCNSL
Intervention(s): Rituximab, Lenalidomide, Methotrexate
Locations: 2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
Molecular Prognosis of Lymphomas of the Central Nervous System (ALYCE-molecular)
Status: Recruiting
Last Changed: Mar 01, 2019
First Received: Mar 01, 2019
Disease(s): Central Nervous System Lymphoma
Intervention(s): Retrospective study
Locations: Service d'hématologie biologique - Centre Hospitalier Lyon Sud - HCL, Pierre-Bénite, France
Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete Response
Status: Recruiting
Last Changed: May 07, 2020
First Received: Jul 15, 2015
Disease(s): Central Nervous System B-Cell Non-Hodgkin Lymphoma
Intervention(s): Cognitive Assessment, Obinutuzumab, Quality-of-Life Assessment
Locations: University of Colorado, Denver, Colorado, United States
Piedmont Hospital, Atlanta, Georgia, United States
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States
Cleveland Clinic Cancer Center/Fairview Hospital, Cleveland, Ohio, United States
... and 7 other locations.
Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS)
Status: Recruiting
Last Changed: Jun 02, 2020
First Received: May 28, 2019
Disease(s): Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma
Intervention(s): TEDD-R, TEDDI-R, Ibrutinib, Cytarabine, Isavuconazole
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland, United States
R-MPV Followed by Nivolumab in Older (≥65) Pts With Previously Untreated Primary CNS Lymphoma
Status: Recruiting
Last Changed: Jan 21, 2020
First Received: Jul 17, 2019
Disease(s): Brain and Nervous System, Eye and Orbit
Intervention(s): Nivolumab, Rituximab, Methotrexate, Vincristine, Procarbazine
Locations: Levine Cancer Institute, Charlotte, North Carolina, United States
Nivolumab and Pomalidomide in Treating Patients With Relapsed or Refractory Central Nervous System Diffuse Large B Cell Lymphoma or Primary Vitreoretinal Diffuse Large B Cell Lymphoma
Status: Recruiting
Last Changed: Feb 19, 2020
First Received: Jan 09, 2019
Disease(s): Recurrent Nervous System Lymphoma, Recurrent Primary Vitreoretinal DLBCL, Refractory Nervous System Lymphoma, Refractory Primary Vitreoretinal DLBCL
Intervention(s): Nivolumab, Pomalidomide
Locations: Mayo Clinic in Florida, Jacksonville, Florida, United States
Mayo Clinic, Rochester, Minnesota, United States
Sintilimab (IBI308) in Refractory or Relapsed PMBCL, PT/NKCL and PCNSL
Status: Recruiting
Last Changed: Aug 12, 2019
First Received: Aug 12, 2019
Disease(s): Primary Mediastinal Large B-Cell Lymphoma, Peripheral T/NK-cell Lymphoma, Primary Central Nervous System Lymphoma
Intervention(s): Sintilimab
Locations: Beijing, Beijing, Beijing, China